Continuous Intravenous Valproate as Abortive Therapy for Pediatric Status Migrainosus

Area of Science:

• Pediatric Neurology
• Emergency Medicine
• Pharmacology

Background:

• Status migrainosus in children often requires effective abortive therapies.
• Continuous intravenous valproate offers pharmacokinetic advantages over bolus dosing for improved safety and therapeutic consistency.
• Reduced serum concentration fluctuations with continuous infusion may lead to fewer adverse effects.

Purpose of the Study:

• To evaluate the efficacy and safety of continuous intravenous valproate for pediatric status migrainosus.
• To assess the therapeutic response and side effect profile of this treatment strategy.

Main Methods:

• Retrospective chart review of 83 pediatric patients with status migrainosus treated between 2009-2012.
• Patients received a 20 mg/kg loading dose followed by a 1 mg/kg/h continuous infusion of valproate.
• Serum valproate levels were monitored, and pain scores were assessed regularly to define response categories.

Main Results:

• An excellent pain reduction response was achieved in 66.2% of patients, with 76% responding within 24 hours.
• Continuous intravenous valproate demonstrated a favorable safety profile, with nausea and vomiting as the primary side effects.
• Serum valproate levels remained within the target therapeutic range (80-100 mcg/mL) in 91.9% of cases at 24 hours.

Conclusions:

• Continuous intravenous valproate is a safe, easily monitored, and effective abortive therapy for pediatric status migrainosus.
• This infusion method provides consistent therapeutic levels and a reduced incidence of adverse events.
• The findings support the use of continuous intravenous valproate as a primary treatment option for this condition in children.